# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Evel Knievel (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-RB001-SYN
- Date: 2026-02-23
- Fictional facility: St. Posthumous Health Center
- Fictional author: Dale Rasmussen, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

First day of hepatitis C treatment. **S**

## History of present illness

Mr. Knievel returns four weeks after the hepatology visit to start sofosbuvir-velpatasvir, which has been approved. He takes carvedilol 6.25 mg daily without dizziness. He has had one drink in the past month and wants to stop altogether. He started aquatic therapy three weeks ago and walks a little farther; pain is about 5 of 10. He has taken no omeprazole, ibuprofen or herbal products. He has had no low glucose readings, abdominal swelling, black stools, confusion or yellow eyes. He has had no thoughts of self-harm. **S**

| Element | Detail |
|---|---|
| Today | Day 1 of 12 weeks of sofosbuvir-velpatasvir |
| Carvedilol | 6.25 mg daily; pulse 68, blood pressure 128/78 |
| Alcohol | One drink in the past month |
| Pain | 5 of 10 with aquatic therapy |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Still tired in the afternoons; no fever |
| Gastrointestinal | Negative | No abdominal swelling, black stools or heartburn |
| Cardiovascular | Negative | No dizziness on standing |
| Musculoskeletal | Positive | Hip and knee pain, 5 of 10; no muscle aches |
| Endocrine | Negative | No shakiness or sweating to suggest low glucose |
| Psychiatric | Negative | Mood steady; PHQ-9 5; no thoughts of self-harm |

6 systems reviewed. **S**

## Current medications

- Metformin 1000 mg oral tablet, one tablet by mouth twice daily with meals **S**
- Acetaminophen 500 mg oral tablet, two tablets by mouth up to twice a day as needed for pain, no more than 2 g a day **S**
- Diclofenac sodium 1% topical gel, 4 g to the knees up to four times a day **S**
- Carvedilol 12.5 mg oral tablet, one tablet daily **S**
- Atorvastatin 20 mg oral tablet, one tablet daily **S**
- Sofosbuvir 400 mg and velpatasvir 100 mg oral tablet, one tablet daily for 12 weeks **S**
- Cholecalciferol (vitamin D3) 50 mcg (2000 units) oral capsule, one capsule daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 128/78 mmHg; pulse 68 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 84.8 kg; BMI 26.8 kg/m². All vital signs are synthetic.

Hemoglobin: 14 g/dL; White cell count: 4.8 10*3/uL; Platelets: 121 10*3/uL (low); Creatinine: 0.9 mg/dL; eGFR (CKD-EPI 2021): 100 mL/min/1.73 m²; Glucose (fasting): 141 mg/dL (high); ALT: 81 U/L (high); AST: 90 U/L (high); Total bilirubin: 1 mg/dL; Albumin: 3.7 g/dL; Calcium: 9.1 mg/dL; 25-hydroxyvitamin D: 17 ng/mL (low); Vitamin B12: 388 pg/mL; TSH: 2.1 mIU/L; AUDIT-C: 1; PHQ-9: 5; Pain (0 to 10): 5. All results are synthetic.

## Change since baseline

- Hemoglobin: 13.9 g/dL at baseline, 14 g/dL at this visit **S**
- White cell count: 4.6 10*3/uL at baseline, 4.8 10*3/uL at this visit **S**
- Platelets: 118 10*3/uL (low) at baseline, 121 10*3/uL (low) at this visit **S**
- Creatinine: 0.92 mg/dL at baseline, 0.9 mg/dL at this visit **S**
- eGFR (CKD-EPI 2021): 97 mL/min/1.73 m² at baseline, 100 mL/min/1.73 m² at this visit **S**
- Glucose (fasting): 162 mg/dL (high) at baseline, 141 mg/dL (high) at this visit **S**
- ALT: 88 U/L (high) at baseline, 81 U/L (high) at this visit **S**
- AST: 96 U/L (high) at baseline, 90 U/L (high) at this visit **S**
- Total bilirubin: 1.1 mg/dL at baseline, 1 mg/dL at this visit **S**
- Albumin: 3.6 g/dL at baseline, 3.7 g/dL at this visit **S**
- AUDIT-C: 7 at baseline, 1 at this visit **S**
- Pain (0 to 10): 7 at baseline, 5 at this visit **S**

## Immunizations given today

- Hepatitis B vaccine (recombinant, CpG adjuvanted), dose 2 of 2 **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; weight 84.8 kg; blood pressure 128/78, pulse 68 |
| Skin | Spider angiomas unchanged; no jaundice or bruising |
| Abdomen | Spleen tip palpable; no ascites |
| Musculoskeletal | Reduced hip rotation; knee crepitus; old forearm fracture deformities |
| Neurological | No asterixis |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Chronic hepatitis C, genotype 1a** (B18.2). Pre-treatment tests within three months are complete: platelets 121, creatinine 0.90 mg/dL with eGFR 100, ALT 81, AST 90 U/L, bilirubin 1.0 mg/dL, albumin 3.7 g/dL, and INR 1.1 in January. The interaction check is unchanged. On-treatment liver tests are optional on this pathway; he will call for jaundice, dark urine or abdominal swelling. As the virus clears, glucose can fall, so he will watch his sensor for lows. **S**
   - Sofosbuvir-velpatasvir one tablet daily from today for 12 weeks; a pill box and phone reminder.
   - Review at the end of treatment.
   - No new medicines or supplements without checking.
2. **Clinically significant portal hypertension** (K76.6). Pulse 68 and blood pressure 128/78 on carvedilol 6.25 mg allow the target dose. **S**
   - Carvedilol 12.5 mg daily from today.
   - Hold a dose and call if systolic pressure falls below 90 or he feels faint.
3. **Vitamin D deficiency** (E55.9). 25-hydroxyvitamin D 17 ng/mL, common in cirrhosis; calcium 9.1 mg/dL and TSH 2.1 are normal; vitamin B12 388 pg/mL on long-term metformin is normal. **S**
   - Vitamin D3 2000 units daily.
   - Bone density scan in two weeks.
   - Recheck vitamin D at the end of treatment.
4. **Type 2 diabetes** (E11.65). Glucose 141 mg/dL fasting; sensor started today. **S**
   - Continue metformin.
   - Sensor review at the end of treatment.
5. **Chronic pain from old fractures** (G89.29). Better with aquatic therapy; no NSAIDs or opioids. **S**
   - Continue aquatic therapy twice a week and the home program.
   - Acetaminophen up to 2 g a day; diclofenac gel to the knees.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Blood count, hepatic function panel and eGFR | Within three months before HCV treatment | Completed today | Hemoglobin 14.0 g/dL, white cells 4.8, platelets 121; creatinine 0.90 mg/dL, eGFR 100; ALT 81, AST 90 U/L, bilirubin 1.0 mg/dL, albumin 3.7 g/dL |
| Laboratory | INR | Within three months before HCV treatment | Up to date | 1.1 in January |
| Medication safety | Drug interaction review | At the start of HCV treatment | Completed today | No proton pump inhibitor, amiodarone or supplements; atorvastatin with muscle-pain monitoring |
| Medication safety | Hypoglycemia monitoring on diabetes medicine during HCV treatment | Throughout treatment | Completed today | Sensor started; he knows how to treat a low |
| Medication safety | Carvedilol titration | Every two to four weeks to the target dose | Completed today | Raised to 12.5 mg daily; pulse 68, blood pressure 128/78 |
| Medication safety | Hepatitis B vaccination, dose 2 | One month after dose 1 | Completed today | Given today; series complete |
| Laboratory | Vitamin D, calcium and TSH (secondary causes of bone loss) | Before bone density testing in a man at risk | Completed today | Vitamin D 17 ng/mL (low); calcium 9.1 mg/dL; TSH 2.1 |
| Laboratory | Vitamin B12 on long-term metformin | Periodically | Completed today | 388 pg/mL, normal |
| Imaging | Bone density (DXA) | Men at risk: cirrhosis, alcohol and prior fractures | Ordered | Booked in two weeks |
| Referral | Physical therapy | For falls and chronic pain | Up to date | Assessed three weeks ago; aquatic therapy twice a week |
| Referral | Diabetic eye examination | Yearly | Referred | Referral made at the last visit; not yet booked |
| Examination | Signs of decompensation (ascites, encephalopathy, jaundice, bleeding) | Each visit in cirrhosis | Completed today | None |
| Survey | Alcohol use (AUDIT-C) | Each visit in liver disease | Completed today | AUDIT-C 1; he plans to stop |
| Survey | Pain score and function | Each visit | Completed today | 5 of 10; walking farther |
| Survey | Depression screen (PHQ-9) | At diagnosis and when treatment changes | Completed today | PHQ-9 5 |

## Goal progress

- Hepatitis C confirmed or excluded and liver disease staged within three weeks. Outcome by 2026-01-26: Chronic hepatitis C, genotype 1a, with compensated cirrhosis staged at two weeks. **S**
- Cure of hepatitis C: HCV RNA not detected 12 or more weeks after treatment. In progress; target 2026-08-17. **S**
- No decompensation (ascites, variceal bleeding, encephalopathy or jaundice); Child-Pugh A and MELD-Na below 15. In progress; target 2026-08-17. **S**
- No alcohol. In progress; target 2026-08-17. **S**
- Pain 4 of 10 or less, walking 30 minutes, with no oral NSAIDs or opioids. In progress; target 2026-08-17. **S**
- Glucose management indicator below 7% without hypoglycemia. In progress; target 2026-08-17. **S**
- Vitamin D replete and osteoporosis treatment started; no falls with injury. In progress; target 2026-08-17. **S**

## Medication changes

- Stopped: Carvedilol 6.25 mg oral tablet, one tablet daily **S**
- Started: Carvedilol 12.5 mg oral tablet, one tablet daily **S**
- Started: Sofosbuvir 400 mg and velpatasvir 100 mg oral tablet, one tablet daily for 12 weeks **S**
- Started: Cholecalciferol (vitamin D3) 50 mcg (2000 units) oral capsule, one capsule daily **S**

## Guideline basis

- AASLD-IDSA HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. Simplified HCV treatment algorithm for treatment-naive adults with compensated cirrhosis (2023), American Association for the Study of Liver Diseases and Infectious Diseases Society of America
- AASLD-IDSA HCV Guidance: Monitoring patients who are starting HCV treatment, are on treatment, or have completed therapy (2026), American Association for the Study of Liver Diseases and Infectious Diseases Society of America
- EPCLUSA (sofosbuvir and velpatasvir) tablets, prescribing information (2025), U.S. National Library of Medicine, DailyMed (Gilead Sciences label)
- de Franchis R, et al. Baveno VII - Renewing consensus in portal hypertension. J Hepatol 2022;76(4):959-974 (PMID 35120736) (2022), Baveno VII Faculty (Journal of Hepatology)
- Kaplan DE, et al. AASLD Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis. Hepatology 2024;79(5):1180-1211 (PMID 37870298) (2024), American Association for the Study of Liver Diseases
- Biggins SW, et al. Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the AASLD. Hepatology 2021;74(2):1014-1048 (PMID 33942342) (2021), American Association for the Study of Liver Diseases
- Crabb DW, et al. Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the AASLD. Hepatology 2020;71(1):306-333 (PMID 31314133) (2019), American Association for the Study of Liver Diseases
- Rakoski M, Goyal P, Spencer-Safier M, et al. Pain management in patients with cirrhosis. Clin Liver Dis (Hoboken) 2018;11(6):135-140 (PMID 30992804) (2018), American Association for the Study of Liver Diseases (Clinical Liver Disease)
- Dowell D, et al. CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022. MMWR Recomm Rep 2022;71(3):1-95 (PMID 36327391) (2022), Centers for Disease Control and Prevention
- American Diabetes Association. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2026. Diabetes Care 2026;49(Suppl 1):S61-S88 (PMID 41358897) (2026), American Diabetes Association
- American Diabetes Association. 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026. Diabetes Care 2026;49(Suppl 1):S132-S149 (PMID 41358894) (2026), American Diabetes Association
- Watts NB, et al. Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2012;97(6):1802-1822 (PMID 22675062) (2012), Endocrine Society
- Unhealthy Alcohol Use in Adolescents and Adults: Screening and Behavioral Counseling Interventions (2018), U.S. Preventive Services Task Force
- Adult Immunization Schedule by Medical Condition and Other Indication (2026), Centers for Disease Control and Prevention
- CMID: Clinical Monitoring Intelligence Database, diabetes type 2, osteoporosis and depression monographs (2026), Aether Forge
- Depression and Suicide Risk in Adults: Screening (2023), U.S. Preventive Services Task Force

## Follow-up

- Bone density scan in two weeks. Review at the end of 12 weeks of treatment. Call for jaundice, dark urine, abdominal swelling, black stools, confusion, faintness or low glucose readings. **S**
- Next scheduled visit 2026-05-18: end of 12 weeks of antiviral treatment: liver tests, glucose monitoring in cirrhosis, osteoporosis, pain, and abstinence. **S**
